Neurologic complications of radiotherapy, chemotherapy, and novel agents used in the treatment of lymphomas
| Neurologic presentation . | Offending agent . |
|---|---|
| Acute encephalopathy | HD-MTX (IV, IT) Ifosfamide Busulfan Cytarabine Immune checkpoint inhibitors CD19-directed CAR T-cell therapy Whole-brain radiation |
| Chronic encephalopathy | HD-MTX Whole-brain radiation |
| PML | Rituximab Alemtuzumab Brentuximab vedotin |
| Aseptic meningitis | Methotrexate (IT) Cytarabine (IT) Immune checkpoint inhibitors |
| Intracranial hemorrhage | Ibrutinib |
| Cerebellar syndrome | High-dose cytarabine |
| Seizures | High-dose busulfan High-dose etoposide CD19-directed CAR T-cell therapy |
| Aphasia | CD19-directed CAR T-cell therapy |
| Myelopathy | Thiotepa (IT) Cytarabine (IT) Immune checkpoint inhibitors Radiation |
| Peripheral neuropathy | Vincristine Vinblastine Carboplatin Thalidomide Lenalidomide Pomalidomide Brentuximab vedotin Polatuzumab vedotin Checkpoint inhibitors Alemtuzumab |
| Guillain-Barré syndrome | Checkpoint inhibitors Alemtuzumab |
| Myositis | Checkpoint inhibitors Brentuximab vedotin |
| Myasthenia gravis | Checkpoint inhibitors |
| Neurologic presentation . | Offending agent . |
|---|---|
| Acute encephalopathy | HD-MTX (IV, IT) Ifosfamide Busulfan Cytarabine Immune checkpoint inhibitors CD19-directed CAR T-cell therapy Whole-brain radiation |
| Chronic encephalopathy | HD-MTX Whole-brain radiation |
| PML | Rituximab Alemtuzumab Brentuximab vedotin |
| Aseptic meningitis | Methotrexate (IT) Cytarabine (IT) Immune checkpoint inhibitors |
| Intracranial hemorrhage | Ibrutinib |
| Cerebellar syndrome | High-dose cytarabine |
| Seizures | High-dose busulfan High-dose etoposide CD19-directed CAR T-cell therapy |
| Aphasia | CD19-directed CAR T-cell therapy |
| Myelopathy | Thiotepa (IT) Cytarabine (IT) Immune checkpoint inhibitors Radiation |
| Peripheral neuropathy | Vincristine Vinblastine Carboplatin Thalidomide Lenalidomide Pomalidomide Brentuximab vedotin Polatuzumab vedotin Checkpoint inhibitors Alemtuzumab |
| Guillain-Barré syndrome | Checkpoint inhibitors Alemtuzumab |
| Myositis | Checkpoint inhibitors Brentuximab vedotin |
| Myasthenia gravis | Checkpoint inhibitors |